Incyte (INCY) Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream as a Treatment for Patients with Vitiligo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Airbnb (ABNB), Lucid (LCID), Four Others to be Added to Nasdaq-100 Index (FTNT) (PANW) (ZS) (DDOG)
December 13, 2021 6:09 AM ESTNasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (Nasdaq: NDX), which will become effective prior to market open on Monday, December 20, 2021.
The following six companies will be added to the Index: Airbnb, Inc. (Nasdaq:... More
NASDAQ (NDAQ) Announces Changes to the Nasdaq-100 Index
December 13, 2021 5:27 AM ESTNasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (Nasdaq: NDX), which will become effective prior to market open on Monday, December 20, 2021.
The following six companies will be added to the Index: Airbnb, Inc, Fortinet, Inc,... More
Incyte (INCY) and MorphoSys (MOR) Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab in Combination with Lenalidomide
December 13, 2021 5:22 AM ESTMorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (NASDAQ: MOR), and Incyte (NASDAQ: INCY) today announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi®) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). These treatments include polatuzumab vedotin plus bendamustine and rituximab (Pola-BR), rituximab plus lenalidomide (R2), and CD19 chimeric antigen receptor T-cell (CAR-T) therapies. The data, which builds on the primary analysis... More
Incyte (INCY) Reports Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib
December 13, 2021 5:18 AM ESTIncyte (Nasdaq: INCY) today announced data from three ongoing Phase 2 studies evaluating parsaclisib, an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3K), for the treatment of patients with relapsed or refractory follicular lymphoma (FL) (CITADEL-203), marginal zone lymphoma (MZL) (CITADEL-204) and mantle cell lymphoma (MCL) (CITADEL-205). These data were accepted as oral presentations at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021), held December 1114, 2021 in Atlanta, Georgia and virtually.
The primary endpoint for the CITADEL-203, -204 and -205 studies is objective response rate (ORR). Key... More
Why EV Lucid (LCID) Shares Soared in Pre Open Trading Today
December 13, 2021 5:09 AM ESTShares of Lucid Group (NASDAQ: LCID) are up nearly 7% in pre-open today after Nasdaq announced it will add the LCID stock to its Nasdaq-100 Index as of December 2021.
Lucid shares will be included together with Airbnb, Inc. (Nasdaq:... More
